Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
In Vivo
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
In Vivo

Advanced Search

  • Home
  • Content
    • Current
    • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Visit iiar on Facebook
  • Follow us on Linkedin
Review ArticleReviewsR

PCSK9 Antibody-based Treatment Strategies for Patients With Statin Intolerance

ERRIKA VOUTYRITSA, CHRISTOS DAMASKOS, PARASKEVI FARMAKI, GEORGIOS KYRIAKOS, EVANGELOS DIAMANTIS, LOURDES VICTORIA QUILES-SÁNCHEZ, ANNA GARMPI, NIKOLAOS GARMPIS, ALEXANDROS PATSOURAS, ATHANASIA STELIANIDI and SPYRIDON SAVVANIS
In Vivo January 2021, 35 (1) 61-68; DOI: https://doi.org/10.21873/invivo.12232
ERRIKA VOUTYRITSA
1NS Christeas Laboratory of Experimental Surgery and Surgical Research, Medical School, National and Kapodistrian University of Athens, Athens, Greece;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CHRISTOS DAMASKOS
2Second Department of Propedeutic Surgery, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
PARASKEVI FARMAKI
3First Department of Pediatrics, Agia Sofia Children’s Hospital, National and Kapodistrian University of Athens, Athens, Greece;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
GEORGIOS KYRIAKOS
4Sección de Endocrinología y Nutrición, Hospital General Universitario Santa Lucia, Cartagena, Spain;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: giorgos6@yahoo.com
EVANGELOS DIAMANTIS
5Department of Endocrinology and Diabetes Center, G. Gennimatas General Hospital, Athens, Greece;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
LOURDES VICTORIA QUILES-SÁNCHEZ
6Centro de Salud Beniel, Murcia, Spain;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ANNA GARMPI
7Internal Medicine Department, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NIKOLAOS GARMPIS
2Second Department of Propedeutic Surgery, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ALEXANDROS PATSOURAS
8Second Department of Internal Medicine, Tzaneio General Hospital of Piraeus, Piraeus, Greece;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ATHANASIA STELIANIDI
3First Department of Pediatrics, Agia Sofia Children’s Hospital, National and Kapodistrian University of Athens, Athens, Greece;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SPYRIDON SAVVANIS
9Department of Internal Medicine, Elpis General Hospital of Athens, Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background: Statin intolerance refers to the inability of a patient to tolerate statin therapy, presenting muscle aches, pains, weakness and muscle inflammation. Thus, numerous patients are not treated with suitable statin-based therapy or take only very low doses. As a result, the desired decrease in low-density lipoprotein cholesterol (LDL-C) is not achieved, resulting in patients at a high risk for cardiovascular events, requiring an alternative lipid-lowering treatment. Common treatments manage to reduce the LDL-C level by up to 20%. Recently, new alternative treatment options have been proved to lower the LDL-C level by up to 70%. These treatment strategies are based on human monoclonal antibodies against protein convertase subtilisin/kexin 9 (PCSK9). Materials and Methods: Herein, we review the efficiency of anti-PCSK9 in treatment of hypercholesterolemic patients with statin intolerance. We focused on the use of PCSK9 inhibitors in statin-intolerant patients and we estimated the clinical results concerning the reduction of the mean LDL-C concentration and the side effects that were observed. Results: In the majority of cases, treatment strategy based on PCSK9 was successful and achieved the end-points. Conclusion: PCSK9 inhibition can be considered as a treatment of option for lipid-lowering in statin-intolerant patients.

  • Anti-PCSK9
  • statin intolerance
  • evolocumab
  • alirocumab
  • hypercholesterolemia

Statin-based therapies are indicated for lowering low-density lipoprotein cholesterol (LDL-C) concentrations and are considered to be a safe option for the majority of patients with elevated LDL. However, a wide range of adverse effects have been attributed to this kind of treatment, indicating statin intolerance. Side effects derived from statin treatment in patients with statin intolerance are muscle symptoms, nausea, dyspepsia and headache and affect patients’ quality of life (1, 2). Various risk factors have been reported, setting patients at a high risk of presenting statin-induced myopathy. The most common risk factors are advanced age, frailty, genetic factors and co-morbidities (3, 4). Moreover, an important factor that affects the risk of developing myopathy is the dosage used, an increased dose results in higher risk.

Concerning the current treatment options for statin-intolerant patients, when statin-based therapy results in adverse side-effects, a washout period is recommended. If symptoms recede, a lower dose of the same statin is recommended. If the patient does not tolerate the given statin, an alternative statin should be considered. The most efficient and potent statins with a long half-life that can be recommended at low doses are atorvastatin, simvastatin, and rosuvastatin; Iess efficient drugs are fluvastatin and pravastatin (5, 6).

Additionally, non-statin therapies have been proven to lower the LDL-C level. For example, ezetimibe reduces LDL-C by 15-20%, by inactivating the Niemann-Pick C1-like 1 protein (NPC1L1) receptor, having few side-effects and being associated with reduced cardiovascular events in combination with a statin therapy (7-9). Other non-statin lipid-lowering therapies include bile acid sequestrants such as cholestyramine and colesevelam. Although these agents are poorly tolerated when they are given at increased doses, they are able to reduce the LDL-C level synergistically with statins (10).

The newest class of agents that are used in statin-intolerant patients are inhibitors of protein convertase subtilisin/kexin type 9 (PCSK9), which have been proven to significantly reduce the LDL-C level. The most commonly used drugs of this category are two monoclonal antibodies, evolocumab and alirocumab. Regarding the molecular pathway, when the LDL-C level in blood is increased, the monoclonal antibody attaches to PCSK9 and as a result, inhibits the interaction between it and the LDL receptor. PCSK9 inhibition results in increased expression of LDL receptors and therefore the LDL-C concentration is reduced. Importantly, these drugs have also been reported to reduce the rate of cardiovascular events (11-16).

The aim of this review was to investigate the utilization of PCSK9 inhibitors in statin-intolerant patients with muscle-related side-effects. The safety and the effectiveness of these agents was assessed.

Materials and Methods

This review article was based on a systematic search conducted in MEDLINE (via PubMed) library in order to retrieve articles focusing on use of PCSK9 inhibitors in statin-intolerant patients. The search strategy was based on the use of key words such as anti-PCSK9 antibodies, statin intolerance, evolocumab, alirocumab and hypercholesterolemia. A total of 61 records were identified. Some of them were only abstracts, whereas others were not completely relevant to the topic. These articles were excluded. Following removal of the duplicates, 10 records remained. The full-text articles assessed for eligibility were 10 and none of them was excluded. The inclusion process is presented in Figure 1.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

PRISMA flow diagram for the current literature review.

Results

In 2012, Giugliano et al. conducted a trial in which the efficiency and the safety of evolocumab, a human monoclonal IgG2 antibody, as a PCSK9 inhibitor were assessed in statin-intolerant hypercholesterolemic patients (Table I) (17). During this study, 631 patients aged 18-80 years on a stable statin dose with hypercholesterolemia were randomly treated with subcutaneous injections of different doses of evolocumab or placebo every 2 weeks or 4 weeks. After 12 weeks, not only was the mean LDL-C level reduced but also no dose-related or dose-frequency-related increase in side-effects were reported. In contrast, in another study, although the LDL-C concentration was reduced, four serious complications were reported during the evolocumab treatment: Coronary artery disease, acute pancreatitis, hip fracture, and syncope, while myalgia was the main treatment-related side-effect during the study, occurring in 15.6% of the patients (Table I) (18).

View this table:
  • View inline
  • View popup
Table I.

Clinical trials conducted in the current literature review.

Another antibody to PCSK9, alirocumab, has also been investigated. Moriarty et al., presented a study in which alirocumab was compared to ezetimibe in patients at cardiovascular risk with statin intolerance due to muscle side-effects (Table I) (19). During this study, 361 patients were treated with subcutaneous and oral placebo for 4 weeks. Patients in whom muscle-related symptoms were observed were excluded. The rest of the patients were randomized to alirocumab, alirocumab plus placebo, ezetimibe, ezetimibe plus placebo, atorvastatin or atorvastatin plus placebo for 24 weeks. According to the clinical findings, alirocumab resulted in greater LDL-C reductions compared to ezetimibe in statin-intolerant patients, while fewer skeletal-muscle side-effects were observed compared to atorvastatin. In line with these findings, the ODYSSEY DM-DYSLIPIDEMIA randomized trial investigated the safety and efficiency of alirocumab in individuals with type 2 diabetes mellitus and mixed dyslipidemia taking the maximally tolerated dose of statin (Table I) (20). A total of 413 individuals were randomized to receive 75-150 mg alirocumab every 2 weeks or lipid-lowering common treatment including no additional lipid-lowering therapy, fenofibrate, ezetimibe, omega-3 fatty acid, and nicotinic acid. Alirocumab proved to be more efficient in reducing the mean non-HDL-C, LDL-C (−43.0%), apolipoprotein B (−32.3%), and total cholesterol (−24.6%). In addition, it was generally well-tolerated and the incidence of treatment-related adverse events were similar to other study cohorts.

In addition, Teramoto et al. investigated the efficiency of alirocumab in lowering LDL-C (Table I) (21). In this study, 163 patients with hypercholesterolemia were randomized to a placebo-controlled study. During the 12-week therapy period, patients will be randomized equally to receive alirocumab subcutaneously (150 mg/4 weeks), placebo (150 mg/4 weeks), alirocumab (150 mg/2 weeks), or placebo (150 mg/2 weeks). The clinical results, the safety and tolerability of alirocumab will be reported in the future.

Cho et al. conducted a trial in which evolocumab was compared to ezetimibe in hypercholesterolemic patients with statin-associated muscle symptoms (Table I) (22). During this study, 307 patients with elevated LDL-C were tested in a 12-week study. Patients were randomized to evolocumab plus ezetimibe (2: 1). The mean LDL-C level was 4.99 mmol/l. Several statin-related complications were observed: Myalgia in 80% of patients, weakness in 39%, and more serious complications in 20%. Moreover, another study group investigated the safety and efficiency of evolocumab up to 2 years in patients with statin intolerance (Table I) (23). During this study, 382 statin-intolerant patients were tested and re-randomized to evolocumab at a dose of 140 mg weekly or 420 mg monthly (2: 1) or to a standard therapy. After year 1, 98% of the patients had been treated with evolocumab plus a standard therapy. The mean LDL-C concentration was 4.97-5.02 mmol/l (range=192-194 mg/dl). A reduction of 13% was observed in patients treated with the standard therapy and 57% in patients treated with evolocumab plus standard therapy in the first year, and 59% in patients treated with evolocumab plus standard therapy in the second year. Regarding adverse effects, muscle-related events were observed in 16% of patients treated with the standard therapy, and in 14% of those treated with evolocumab plus the standard therapy at year 1, and in 11% of the patients treated with evolocumab plus the standard therapy at year 2. According to the clinical findings, evolocumab plus the standard therapy was shown to be safe, tolerable, and efficient for up to 2 years in statin-intolerant patients.

In the same year, Nissen et al., reported on the efficiency of evolocumab compared to ezetimibe in hypercholesterolemic patients during a 24-week trial (Table I) (24). Patients treated with 420 mg evolocumab monthly compared to 10 mg ezetimibe daily managed to attain LDL-C <70 mg/dl. As a result, evolocumab gave promising results compared with ezetimibe in statin-intolerant patients and allowed researchers to better understand the potential role of PCSK9 inhibitors in the treatment of these challenging patients.

Sbrana et al. enrolled 18 individuals, with a mean age of 62 years, with hypercholesterolemia, cardiovascular disease, and statin intolerance (Table I) (25). The efficiency of PCSK9 inhibitors was investigated. Evolocumab was administered to 15 patients, and alirocumab to three. After 3 months of therapy, a decrease in total cholesterol, LDL-C and Lp(a) levels was achieved. Importantly, in five patients, the level of LDL-C was reduced to <70 mg/dl, seven presented LDL-C levels between 71 and 100 mg/dl, and six continued to have LDL-C levels above 100 mg/dl. Adverse side-effects occurred in two patients treated with evolocumab. According to the results, PCSK9 inhibitors were found to be novel therapeutic tools for statin-intolerant patients with hypercholesterolemia. However, deeper investigation is needed.

Finally, Shapiro et al., conducted a trial, in which LDL-C and Lp(a) lowering by evolocumab was investigated (Table I) (26). In this study, 895 patients with hypercholesterolemia, or statin intolerance participated in a 12-week study. Baseline mean level of LDL-C was 133.6 mg/dl and the median Lp(a) level was 46.4 mg/dl. A discordant response was detected in 165 patients. Moreover, the prevalence of discordance increased when considering those with baseline Lp(a) concentrations >30 mg/dl (26.5%) or >50 mg/dl (28.6%). On the basis of these data, high prevalence of discordance in LDL-C and Lp(a) reduction in the case of evolocumab was demonstrated. As a result, evolocumab provides promising results that need further investigation.

Discussion

Statin intolerance is a common problem among patients treated with statins (27). These patients, being unable to tolerate statin therapy, present muscle-related complications. Therefore, various alternatives treatment options have been reported in order to reduce the LDL-C concentration (28-32). PCSK9 inhibitors have been shown to resulted in a decrease of LDL-C level by up to 70% and have been approved for patients with primary hypercholesterolemia, for patients with statin intolerance and for patients with atherosclerotic cardiovascular disease requiring LDL-C lowering (33, 34).

According to a published review, PCSK9 inhibitors have been a preferred treatment for patients with statin intolerance (35, 36). In particular, two monoclonal antibodies, evolocumab and alirocumab, are considered as treatment of choice, resulting in LDL-C reduction >50%. Arilocumab is associated with a low rate of muscle complications, while evolocumab is related to significantly great reduction of LDL-C concentrations without presenting muscle-related adverse events.

In a recent review, it was suggested that in patients with statin intolerance, presenting muscle pain, treatment with another statin should be recommended (37). The most effective and tolerable statins that patients can be treated with are atorvastatin and rosuvastatin. Moreover, an alternative agent for patients who are not able to tolerate any of the statins is ezetimibe. However, this review also suggests that if LDL cholesterol targets are not achieved, PCSK9 inhibitors may be a valuable option. In patients at high risk of cardiovascular events, these inhibitors can be considered as a suitable treatment tool, resulting in good results.

On the other hand, there have been reports arguing against treatment with PCSK9 inhibitors, such as evolocumab, in statin-intolerant patients (38). In these studies, it was indicated that although preliminary clinical findings were promising, long-term outcomes were controversial, as PCSK9 inhibitors have not yet been proved to reduce cardiovascular events. Moreover, it was suggested that PCSK9 inhibitors are themselves associated with muscle-related adverse effects. Additionally, PCSK9 inhibitor-based therapies are costly and, as a result, are an inappropriate treatment option. According to their findings cardiovascular and noncardiovascular mortality was reduced in patients receiving statin-based therapy, while PCSK9 inhibitors need further investigation as LDL-C lowering therapy.

Recently a review suggested that the better choice for statin-intolerant patients is the re-initiation of therapy with an alternative statin which is related to better persistence (39). Higher tolerance is linked to atorvastatin and rosuvastatin. Restarting therapy based on a different statin may allow clinicians to achieve better therapy selection. Given that statin-taking behaviors may differ, this review recommended that restarting therapy with a different statin can lead to better outcomes. However, innovative strategies need to be undertaken to improve statin compliance.

Studies that will primarily test the effects of monoclonal antibodies to PCSK9 on long-term cardiovascular results should be conducted in order to determine whether the documented LDL-C reduction and various other promising impacts on short-term clinical findings lead to long-term cardiovascular benefit (40). The promising and meaningful evidence of the clinical benefits provided of these agents should lead to cost-effectiveness analyses. Whether this treatment option is effective for cardiovascular risk reduction remains to be determined. The expected novel insights from ongoing trials will notably influence future suggestions of these promising therapies for challenging statin-intolerant patients.

Conclusion

In conclusion, numerous studies have been published about the usefulness of PCSK9 inhibition as a treatment option for lipid-lowering in statin-intolerant patients. However, further clinical trials should be conducted and deeper investigation is needed concerning the safety and the efficiency of this treatment option.

Footnotes

  • Authors’ Contributions

    Savvanis S. and Diamantis E. designed the study. Voutyritsa E., Farmaki P. and Patsouras A. wrote the article. Voutyritsa E., Farmaki P., Diamantis E., Quiles-Sánchez LV. and Kyriakos G. collected the data. Quiles-Sánchez LV., Kyriakos G. Stelianidi A. offered scientific advice. Diamantis E., Damaskos C., Garmpi A., Garmpis N. revised the article. Savvanis S. was the supervisor.

  • This article is freely accessible online.

  • Conflicts of Interest

    The Authors report no conflicts of interest in this work.

  • Received August 1, 2020.
  • Revision received August 31, 2020.
  • Accepted September 7, 2020.
  • Copyright© 2021, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved

References

  1. ↵
    1. Sattar N,
    2. Preiss D,
    3. Murray HM,
    4. Welsh P,
    5. Buckley BM,
    6. de Craen AJ,
    7. Seshasai SR,
    8. McMurray JJ,
    9. Freeman DJ,
    10. Jukema JW,
    11. Macfarlane PW,
    12. Packard CJ,
    13. Stott DJ,
    14. Westendorp RG,
    15. Shepherd J,
    16. Davis BR,
    17. Pressel SL,
    18. Marchioli R,
    19. Marfisi RM,
    20. Maggioni AP,
    21. Tavazzi L,
    22. Tognoni G,
    23. Kjekshus J,
    24. Pedersen TR,
    25. Cook TJ,
    26. Gotto AM,
    27. Clearfield MB,
    28. Downs JR,
    29. Nakamura H,
    30. Ohashi Y,
    31. Mizuno K,
    32. Ray KK and
    33. Ford I
    : Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials. Lancet 375: 735-742, 2010. PMID: 20167359. DOI: 10.1016/S0140-6736(09)61965-6
    OpenUrlCrossRefPubMed
  2. ↵
    1. Macedo AF,
    2. Taylor FC,
    3. Casas JP,
    4. Adler A,
    5. Prieto-Merino D and
    6. Ebrahim S
    : Unintended effects of statins from observational studies in the general population: systematic review and meta-analysis. BMC Med 12: 51, 2014. PMID: 24655568. DOI: 10.1186/1741-7015-12-51
    OpenUrlCrossRefPubMed
  3. ↵
    1. Chatzizisis YS,
    2. Koskinas KC,
    3. Misirli G,
    4. Vaklavas C,
    5. Hatzitolios A and
    6. Giannoglou GD
    : Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment. Drug Saf 33: 171-187, 2010. PMID: 20158283. DOI: 10.2165/11319380-000000000-00000
    OpenUrlCrossRefPubMed
  4. ↵
    1. Stroes ES,
    2. Thompson PD,
    3. Corsini A,
    4. Vladutiu GD,
    5. Raal FJ,
    6. Ray KK,
    7. Roden M,
    8. Stein E,
    9. Tokgözoğlu L,
    10. Nordestgaard BG,
    11. Bruckert E,
    12. De Backer G,
    13. Krauss RM,
    14. Laufs U,
    15. Santos RD,
    16. Hegele RA,
    17. Hovingh GK,
    18. Leiter LA,
    19. Mach F,
    20. März W,
    21. Newman CB,
    22. Wiklund O,
    23. Jacobson TA,
    24. Catapano AL,
    25. Chapman MJ,
    26. Ginsberg HN and European Atherosclerosis Society Consensus Panel
    : Statin-associated muscle symptoms: impact on statin therapy. European Atherosclerosis Society consensus panel statement on assessment, etiology and management. Eur Heart J 36: 1012-1022, 2015. PMID: 25694464. DOI: 10.1093/eurheartj/ehv043
    OpenUrlCrossRefPubMed
  5. ↵
    1. Bruckert E,
    2. Hayem G,
    3. Dejager S,
    4. Yau C and
    5. Begaud B
    : Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients–the PRIMO study. Cardiovasc Drugs Ther 19: 403-414, 2005. PMID: 16453090. DOI: 10.1007/s10557-005-5686-z
    OpenUrlCrossRefPubMed
  6. ↵
    1. Jones P,
    2. Kafonek S,
    3. Laurora I and
    4. Hunninghake D
    : Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 81: 582-587, 1998. PMID: 9514454. DOI: 10.1016/s0002-9149(97)00965-x
    OpenUrlCrossRefPubMed
  7. ↵
    1. Norata GD,
    2. Ballantyne CM and
    3. Catapano AL
    : New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs. Eur Heart J 34: 1783-1789, 2013. PMID: 23509227. DOI: 10.1093/eurheartj/eht088
    OpenUrlCrossRefPubMed
    1. Cannon CP,
    2. Blazing MA,
    3. Giugliano RP,
    4. McCagg A,
    5. White JA,
    6. Theroux P,
    7. Darius H,
    8. Lewis BS,
    9. Ophuis TO,
    10. Jukema JW,
    11. De Ferrari GM,
    12. Ruzyllo W,
    13. De Lucca P,
    14. Im K,
    15. Bohula EA,
    16. Reist C,
    17. Wiviott SD,
    18. Tershakovec AM,
    19. Musliner TA,
    20. Braunwald E,
    21. Califf RM and IMPROVE-IT Investigators
    : Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 372: 2387-2397, 2015. PMID: 26039521. DOI: 10.1056/NEJMoa1410489
    OpenUrlCrossRefPubMed
  8. ↵
    1. Catapano AL and
    2. Ference BA
    : IMPROVE-IT and genetics reaffirm the causal role of LDL in cardiovascular disease. Atherosclerosis 241: 498-501, 2015. PMID: 26091974. DOI: 10.1016/j.atherosclerosis.2015.06.008
    OpenUrlCrossRefPubMed
  9. ↵
    1. Rifkind BM
    : Lipid research clinics coronary primary prevention trial: Results and implications. Am J Cardiol 54: 30C-34C, 1984. PMID: 6382999. DOI: 10.1016/0002-9149(84)90854-3
    OpenUrlCrossRefPubMed
  10. ↵
    1. Bergeron N,
    2. Phan BA,
    3. Ding Y,
    4. Fong A and
    5. Krauss RM
    : Proprotein convertase subtilisin/kexin type 9 inhibition: A new therapeutic mechanism for reducing cardiovascular disease risk. Circulation 132: 1648-1666, 2015. PMID: 26503748. DOI: 10.1161/CIRCULATIONAHA.115.016080
    OpenUrlAbstract/FREE Full Text
    1. Abifadel M,
    2. Varret M,
    3. Rabes JP,
    4. Allard D,
    5. Ouguerram K,
    6. Devillers M,
    7. Cruaud C,
    8. Benjannet S,
    9. Wickham L,
    10. Erlich D,
    11. Derré A,
    12. Villéger L,
    13. Farnier M,
    14. Beucler I,
    15. Bruckert E,
    16. Chambaz J,
    17. Chanu B,
    18. Lecerf JM,
    19. Luc G,
    20. Moulin P,
    21. Weissenbach J,
    22. Prat A,
    23. Krempf M,
    24. Junien C,
    25. Seidah NG and
    26. Boileau C
    : Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 34: 154-156, 2003. PMID: 12730697. DOI: 10.1038/ng1161
    OpenUrlCrossRefPubMed
    1. Gouni-Berthold I
    : PCSK9 antibodies: A new class of lipid-lowering drugs. Atheroscler Suppl 18: 21-27, 2015. PMID: 25936300. DOI: 10.1016/j.atherosclerosissup.2015.02.003
    OpenUrlCrossRef
    1. Gouni-Berthold I,
    2. Descamps OS,
    3. Fraass U,
    4. Hartfield E,
    5. Allcott K,
    6. Dent R and
    7. März W
    : Systematic review of published phase 3 data on anti-PCSK9 monoclonal antibodies in patients with hypercholesterolaemia. Br J Clin Pharmacol 82: 1412-1443, 2016. PMID: 27478094. DOI: 10.1111/bcp.13066
    OpenUrlCrossRef
    1. Sabatine MS,
    2. Giugliano RP,
    3. Wiviott SD,
    4. Raal FJ,
    5. Blom DJ,
    6. Robinson J,
    7. Ballantyne CM,
    8. Somaratne R,
    9. Legg J,
    10. Wasserman SM,
    11. Scott R,
    12. Koren MJ,
    13. Stein EA and Opst LDL Cholesterol (OSLER) Investigators
    : Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 372: 1500-1509, 2015. PMID: 25773607. DOI: 10.1056/NEJMoa1500858
    OpenUrlCrossRefPubMed
  11. ↵
    1. Robinson JG,
    2. Farnier M,
    3. Krempf M,
    4. Bergeron J,
    5. Luc G,
    6. Averna M,
    7. Stroes ES,
    8. Langslet G,
    9. Raal FJ,
    10. El Shahawy M,
    11. Koren MJ,
    12. Lepor NE,
    13. Lorenzato C,
    14. Pordy R,
    15. Chaudhari U,
    16. Kastelein JJ and ODYSSEY Long-term Investigators
    : Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 372: 1489-1499, 2015. PMID: 25773378. DOI: 10.1056/NEJMoa1501031
    OpenUrlCrossRefPubMed
  12. ↵
    1. Giugliano RP,
    2. Desai NR,
    3. Kohli P,
    4. Rogers WJ,
    5. Somaratne R,
    6. Huang F,
    7. Liu T,
    8. Mohanavelu S,
    9. Hoffman EB,
    10. McDonald ST,
    11. Abrahamsen TE,
    12. Wasserman SM,
    13. Scott R,
    14. Sabatine MS and LAPLACE-TIMI 57 Investigators
    : Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): A randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet 380: 2007-2017, 2007. PMID: 23141813. DOI: 10.1016/S0140-6736(12)61770-X
    OpenUrlCrossRef
  13. ↵
    1. Sullivan D,
    2. Olsson AG,
    3. Scott R,
    4. Kim JB,
    5. Xue A,
    6. Gebski V,
    7. Wasserman SM and
    8. Stein EA
    : Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: The GAUSS randomized trial. JAMA 308: 2497-2506, 2012. PMID: 23128163. DOI: 10.1001/jama.2012.25790
    OpenUrlCrossRefPubMed
  14. ↵
    1. Moriarty PM,
    2. Thompson PD,
    3. Cannon CP,
    4. Guyton JR,
    5. Bergeron J,
    6. Zieve FJ,
    7. Bruckert E,
    8. Jacobson TA,
    9. Kopecky SL,
    10. Baccara-Dinet MT,
    11. Du Y,
    12. Pordy R,
    13. Gipe DA and ODYSSEY ALTERNATIVE Investigators
    : Efficacy and safety of alirocumab vs. ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol 9: 758-769, 2015. PMID: 26687696. DOI: 10.1016/j.jacl.2015.08.006
    OpenUrlCrossRefPubMed
  15. ↵
    1. Müller-Wieland D,
    2. Leiter LA,
    3. Cariou B,
    4. Letierce A,
    5. Colhoun HM,
    6. Del Prato S,
    7. Henry RR,
    8. Tinahones FJ,
    9. Aurand L,
    10. Maroni J,
    11. Ray KK and
    12. Bujas-Bobanovic M
    : Alirocumab vs. usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial. Diabetes Obes Metab 20: 1479-1489, 2018. PMID: 29436756. DOI: 10.1111/dom.13257
    OpenUrlCrossRef
  16. ↵
    1. Teramoto T,
    2. Kondo A,
    3. Kiyosue A,
    4. Harada-Shiba M,
    5. Ishigaki Y,
    6. Tobita K,
    7. Kawabata Y,
    8. Ozaki A,
    9. Baccara-Dinet MT and
    10. Sata M
    : Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale. Lipids Health Dis 16: 121, 2017. PMID: 28623954. DOI: 10.1186/s12944-017-0513-7
    OpenUrlCrossRef
  17. ↵
    1. Cho L,
    2. Rocco M,
    3. Colquhoun D,
    4. Sullivan D,
    5. Rosenson RS,
    6. Dent R,
    7. Xue A,
    8. Scott R,
    9. Wasserman SM and
    10. Stroes E
    : Clinical profile of statin intolerance in the phase 3 GAUSS-2 Study. Cardiovasc Drugs Ther 30: 297-304, 2016. PMID: 26936841. DOI: 10.1007/s10557-016-6655-4
    OpenUrlCrossRef
  18. ↵
    1. Cho L,
    2. Dent R,
    3. Stroes ESG,
    4. Stein EA,
    5. Sullivan D,
    6. Ruzza A,
    7. Flower A,
    8. Somaratne R and
    9. Rosenson RS
    : Persistent safety and efficacy of evolocumab in patients with statin intolerance: A subset analysis of the OSLER open-label extension studies. Cardiovasc Drugs Ther 32: 365-372, 2018. PMID: 30073585. DOI: 10.1007/s10557-018-6817-7
    OpenUrlCrossRefPubMed
  19. ↵
    1. Nissen SE,
    2. Dent-Acosta RE,
    3. Rosenson RS,
    4. Stroes E,
    5. Sattar N,
    6. Preiss D,
    7. Mancini GB,
    8. Ballantyne CM,
    9. Catapano A,
    10. Gouni-Berthold I,
    11. Stein EA,
    12. Xue A,
    13. Wasserman SM,
    14. Scott R,
    15. Thompson PD and GAUSS-3 Investigators
    : Comparison of PCSK9 inhibitor evolocumab vs. ezetimibe in statin-intolerant patients: Design of the goal achievement after utilizing an anti-PCSK9 antibody in statin-intolerant subjects 3 (GAUSS-3) Trial. Clin Cardiol 39: 137-144, 2016. PMID: 26946077. DOI: 10.1002/clc.22518
    OpenUrlCrossRef
  20. ↵
    1. Sbrana F,
    2. Dal Pino B,
    3. Bigazzi F,
    4. Ripoli A,
    5. Passino C,
    6. Gabutti A,
    7. Pasanisi EM,
    8. Petersen C,
    9. Valleggi A,
    10. Todiere G,
    11. Barison A,
    12. Giannoni A,
    13. Panchetti L,
    14. Becherini F,
    15. Pianelli M,
    16. Luciani R and
    17. Sampietro T
    : Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else? Eur J Prev Cardiol 24: 1528-1531, 2017. PMID: 28555526. DOI: 10.1177/2047487317712419
    OpenUrlCrossRef
  21. ↵
    1. Shapiro MD,
    2. Minnier J,
    3. Tavori H,
    4. Kassahun H,
    5. Flower A,
    6. Somaratne R and
    7. Fazio S
    : Relationship between low-density lipoprotein cholesterol and lipoprotein(a) Lowering in response to PCSK9 inhibition with evolocumab. J Am Heart Assoc 8: e010932, 2019. PMID: 30755061. DOI: 10.1161/JAHA.118.010932
    OpenUrlCrossRef
  22. ↵
    1. Snejdrlova M,
    2. Altschmiedova T,
    3. Vrablik M,
    4. Stulc T,
    5. Lastuvka J,
    6. Lanska V and
    7. Ceska R
    : Statin intolerance in clinical practice. Curr Atheroscler Rep 22: 27, 2020. PMID: 32495058. DOI: 10.1007/s11883-020-00845-9
    OpenUrlCrossRef
  23. ↵
    1. Roh JW,
    2. Chun KH,
    3. Kang M,
    4. Lee CJ,
    5. Oh J,
    6. Shim CY,
    7. Ahn CM,
    8. Kim JS,
    9. Kim BK,
    10. Park S,
    11. Chang HJ,
    12. Hong GR,
    13. Ko YG,
    14. Kang SM,
    15. Choi D,
    16. Ha JW,
    17. Hong MK,
    18. Jang Y and
    19. Lee SH
    : PRavastatin versus FlUVastatin After Statin Intolerance: The PRUV-intolerance study with propensity score matching. Am J Med 132: 1320-1326.e1, 2019. PMID: 31278931. DOI: 10.1016/j.amjmed.2019.06.003
    OpenUrlCrossRef
    1. Soran H,
    2. France M,
    3. Adam S,
    4. Iqbal Z,
    5. Ho JH and
    6. Durrington PN
    : Quantitative evaluation of statin effectiveness versus intolerance and strategies for management of intolerance. Atherosclerosis 306: 33-40, 2020. PMID: 32683135. DOI: 10.1016/j.atherosclerosis.2020.06.023
    OpenUrlCrossRef
    1. Marazzi G,
    2. Campolongo G,
    3. Pelliccia F,
    4. Calabrò Md P,
    5. Cacciotti L,
    6. Vitale C,
    7. Massaro R,
    8. Volterrani M and
    9. Rosano G
    : Usefulness of low-dose statin plus ezetimibe and/or nutraceuticals in patients with coronary artery disease intolerant to high-dose statin treatment. Am J Cardiol 123: 233-238, 2019. PMID: 30420184. DOI: 10.1016/j.amjcard.2018.09.041
    OpenUrlCrossRef
    1. Scolaro B,
    2. Nogueira MS,
    3. Paiva A,
    4. Bertolami A,
    5. Barroso LP,
    6. Vaisar T,
    7. Heffron SP,
    8. Fisher EA and
    9. Castro IA
    : Statin dose reduction with complementary diet therapy: A pilot study of personalized medicine. Mol Metab 11: 137-144, 2018. PMID: 29503145. DOI: 10.1016/j.molmet.2018.02.005
    OpenUrlCrossRef
  24. ↵
    1. Laufs U,
    2. Banach M,
    3. Mancini GBJ,
    4. Gaudet D,
    5. Bloedon LT,
    6. Sterling LR,
    7. Kelly S and
    8. Stroes ESG
    : Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance. J Am Heart Assoc 8: e011662, 2019. PMID: 30922146. DOI: 10.1161/JAHA.118.011662
    OpenUrlCrossRef
  25. ↵
    1. Cannon CP,
    2. Sanchez RJ,
    3. Klimchak AC,
    4. Khan I,
    5. Sasiela WJ,
    6. Reynolds MR and
    7. Rosenson RS
    : Simulation of the impact of statin intolerance on the need for ezetimibe and/or proprotein convertase subtilisin/kexin type 9 inhibitor for meeting low-density lipoprotein cholesterol goals in a population with atherosclerotic cardiovascular disease. Am J Cardiol 23: 1202-1207, 2019. PMID: 30736965. DOI: 10.1016/j.amjcard.2019.01.028
    OpenUrlCrossRef
  26. ↵
    1. Schreml J and
    2. Gouni-Berthold I
    : Role of anti-PCSK9 antibodies in the treatment of patients with statin intolerance. Curr Med Chem 25: 1538-1548, 2018. PMID: 28618994. DOI: 10.2174/0929867324666170616111647
    OpenUrlCrossRef
  27. ↵
    1. Davidson ER,
    2. Snider MJ,
    3. Bartsch K,
    4. Hirsch A,
    5. Li J and
    6. Larry J
    : Tolerance of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with self-reported statin intolerance. J Pharm Pract 33: 276-282, 2020. PMID: 30222031. DOI: 10.1177/0897190018799218
    OpenUrlCrossRef
  28. ↵
    1. Alonso R,
    2. Cuevas A and
    3. Cafferata A
    : Diagnosis and management of statin intolerance. J Atheroscler Thromb 26: 207-215, 2019. PMID: 30662020. DOI: 10.5551/jat.RV17030
    OpenUrlCrossRef
  29. ↵
    1. Fischer S and
    2. Julius U
    : Management of patients with statin intolerance. Atheroscler Suppl 30: 33-37, 2017. PMID: 29096858. DOI: 10.1016/j.atherosclerosissup.2017.05.013
    OpenUrlCrossRef
  30. ↵
    1. Waters DD,
    2. Hsue PY and
    3. Bangalore S
    : PCSK9 inhibitors for statin intolerance? JAMA 315: 1571-1572, 2016. PMID: 27039138. DOI: 10.1001/jama.2016.3670
    OpenUrlCrossRef
  31. ↵
    1. Ofori-Asenso R,
    2. Ilomaki J,
    3. Tacey M,
    4. Zomer E,
    5. Curtis AJ,
    6. Si S,
    7. Zullo AR,
    8. Korhonen MJ,
    9. Bell JS,
    10. Zoungas S and
    11. Liew D
    : Switching, discontinuation, and reinitiation of statins among older adults. J Am Coll Cardiol 72: 2675-2677, 2018. PMID: 30466527. DOI: 10.1016/j.jacc.2018.08.2191
    OpenUrlFREE Full Text
  32. ↵
    1. Koskinas K,
    2. Wilhelm M and
    3. Windecker S
    : Current treatment of dyslipidaemia: PCSK9 inhibitors and statin intolerance. Swiss Med Wkly 146: w14333, 2016. PMID: 27400448. DOI: 10.4414/smw.2016.14333
    OpenUrlCrossRef
View Abstract
PreviousNext
Back to top

In this issue

In Vivo: 35 (1)
In Vivo
Vol. 35, Issue 1
January-February 2021
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on In Vivo.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
PCSK9 Antibody-based Treatment Strategies for Patients With Statin Intolerance
(Your Name) has sent you a message from In Vivo
(Your Name) thought you would like to see the In Vivo web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
4 + 3 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
PCSK9 Antibody-based Treatment Strategies for Patients With Statin Intolerance
ERRIKA VOUTYRITSA, CHRISTOS DAMASKOS, PARASKEVI FARMAKI, GEORGIOS KYRIAKOS, EVANGELOS DIAMANTIS, LOURDES VICTORIA QUILES-SÁNCHEZ, ANNA GARMPI, NIKOLAOS GARMPIS, ALEXANDROS PATSOURAS, ATHANASIA STELIANIDI, SPYRIDON SAVVANIS
In Vivo Jan 2021, 35 (1) 61-68; DOI: 10.21873/invivo.12232

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
PCSK9 Antibody-based Treatment Strategies for Patients With Statin Intolerance
ERRIKA VOUTYRITSA, CHRISTOS DAMASKOS, PARASKEVI FARMAKI, GEORGIOS KYRIAKOS, EVANGELOS DIAMANTIS, LOURDES VICTORIA QUILES-SÁNCHEZ, ANNA GARMPI, NIKOLAOS GARMPIS, ALEXANDROS PATSOURAS, ATHANASIA STELIANIDI, SPYRIDON SAVVANIS
In Vivo Jan 2021, 35 (1) 61-68; DOI: 10.21873/invivo.12232
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Conclusion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • An Update on Clinicopathological, Imaging and Genetic Features of Desmoplastic Fibroblastoma (Collagenous Fibroma)
  • Therapeutic Application of Mesenchymal Stem Cells for Cochlear Regeneration
  • Sensitivity, Specificity and the Diagnostic Accuracy of PET/CT for Axillary Staging in Patients With Stage I-III Cancer: A Systematic Review of The Literature
Show more Reviews

Similar Articles

Keywords

  • Anti-PCSK9
  • statin intolerance
  • evolocumab
  • alirocumab
  • hypercholesterolemia
In Vivo

© 2021 In Vivo

Powered by HighWire